Full Fed. Circ. Urged To Review 'Unclear' Double-Patent Rules
Generics maker Hikma asked the full Federal Circuit Monday to rehear a decision that a Novartis cancer drug patent is not invalid for double-patenting, saying the ruling conflicts with precedent and...To view the full article, register now.
Already a subscriber? Click here to view full article